Regeneron Pharmaceuticals (REGN) Shares Outstanding (Weighted Average) (2009 - 2026)

Regeneron Pharmaceuticals has reported Shares Outstanding (Weighted Average) for 18 years, with the latest figure at $104.0 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) fell 2.53% year-over-year to $104.0 million; the trailing twelve-month figure through Mar 2026 stood at $104.0 million (down 2.53% YoY), and the FY2025 full-year result was $104.6 million, down 3.06% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $104.0 million, down from $104.6 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $108.1 million in Q2 2024, with the low at $103.6 million in Q3 2025.
• Average Shares Outstanding (Weighted Average) over 5 years is $106.6 million, with a median of $107.0 million recorded in 2023.
• Year-over-year, Shares Outstanding (Weighted Average) grew 2.57% in 2022 and fell 4.07% in 2025.
• Tracing REGN's Shares Outstanding (Weighted Average) over 5 years: stood at $107.1 million in 2022, then declined by 0.37% to $106.7 million in 2023, then gained by 1.12% to $107.9 million in 2024, then fell by 3.06% to $104.6 million in 2025, then decreased by 0.57% to $104.0 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $104.0 million (Q1 2026), $104.6 million (Q4 2025), and $103.6 million (Q3 2025), per Business Quant data.

Peer Comparison